These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 12520557

  • 41. A comparison of multiple testing procedures for the gold standard non-inferiority trial.
    Röhmel J, Pigeot I.
    J Biopharm Stat; 2010 Sep; 20(5):911-26. PubMed ID: 20721781
    [Abstract] [Full Text] [Related]

  • 42. Bayesian approach to the design and analysis of non-inferiority trials for anti-infective products.
    Gamalo MA, Tiwari RC, LaVange LM.
    Pharm Stat; 2014 Sep; 13(1):25-40. PubMed ID: 23913880
    [Abstract] [Full Text] [Related]

  • 43. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
    Lachin JM.
    Stat Med; 2006 Oct 15; 25(19):3348-65. PubMed ID: 16345019
    [Abstract] [Full Text] [Related]

  • 44. Sample size re-estimation in group-sequential response-adaptive clinical trials.
    Morgan CC.
    Stat Med; 2003 Dec 30; 22(24):3843-57. PubMed ID: 14673942
    [Abstract] [Full Text] [Related]

  • 45. Therapeutic equivalence: fallacies and falsification.
    Garrett AD.
    Stat Med; 2003 Mar 15; 22(5):741-62. PubMed ID: 12587103
    [Abstract] [Full Text] [Related]

  • 46. Choice of lambda-margin and dependency of non-inferiority trials.
    Tsong Y, Levenson M, Zhang J, Zhong J.
    Stat Med; 2008 Feb 20; 27(4):520-8. PubMed ID: 17617797
    [Abstract] [Full Text] [Related]

  • 47. Re-formulating non-inferiority trials as superiority trials: The case of binary outcomes.
    Durkalski VL, Berger VW.
    Biom J; 2009 Feb 20; 51(1):185-92. PubMed ID: 19197960
    [Abstract] [Full Text] [Related]

  • 48. Sample size estimation for non-inferiority trials of time-to-event data.
    Crisp A, Curtis P.
    Pharm Stat; 2008 Feb 20; 7(4):236-44. PubMed ID: 17583558
    [Abstract] [Full Text] [Related]

  • 49. Flexible two-stage design with sample size reassessment for survival trials.
    Desseaux K, Porcher R.
    Stat Med; 2007 Nov 30; 26(27):5002-13. PubMed ID: 17577242
    [Abstract] [Full Text] [Related]

  • 50. Pairwise non-parametric non-inferiority tests in 3 x 3 cross-over trials: should we adjust for period?
    Duchateau L, Janssen P.
    Stat Med; 2005 May 30; 24(10):1525-36. PubMed ID: 15761908
    [Abstract] [Full Text] [Related]

  • 51. A comparison of intent-to-treat and per-protocol results in antibiotic non-inferiority trials.
    Brittain E, Lin D.
    Stat Med; 2005 Jan 15; 24(1):1-10. PubMed ID: 15532089
    [Abstract] [Full Text] [Related]

  • 52. Assessment of blinding in clinical trials.
    Bang H, Ni L, Davis CE.
    Control Clin Trials; 2004 Apr 15; 25(2):143-56. PubMed ID: 15020033
    [Abstract] [Full Text] [Related]

  • 53. Exact unconditional tests for testing non-inferiority in matched-pairs design.
    Sidik K.
    Stat Med; 2003 Jan 30; 22(2):265-78. PubMed ID: 12520561
    [Abstract] [Full Text] [Related]

  • 54. Evaluation of the statistical power for multiple tests: a case study.
    Yeo A, Qu Y.
    Pharm Stat; 2009 Jan 30; 8(1):5-11. PubMed ID: 18381588
    [Abstract] [Full Text] [Related]

  • 55. Increasing the sample size when the unblinded interim result is promising.
    Chen YH, DeMets DL, Lan KK.
    Stat Med; 2004 Apr 15; 23(7):1023-38. PubMed ID: 15057876
    [Abstract] [Full Text] [Related]

  • 56. Methodology of superiority vs. equivalence trials and non-inferiority trials.
    Christensen E.
    J Hepatol; 2007 May 15; 46(5):947-54. PubMed ID: 17412447
    [Abstract] [Full Text] [Related]

  • 57. Determining equivalence and the impact of sample size in anti-infective studies: a point to consider.
    Bristol DR.
    J Biopharm Stat; 1996 Jul 15; 6(3):319-26. PubMed ID: 8854235
    [Abstract] [Full Text] [Related]

  • 58. Group sequential t-test for clinical trials with small sample sizes across stages.
    Shao J, Feng H.
    Contemp Clin Trials; 2007 Sep 15; 28(5):563-71. PubMed ID: 17434814
    [Abstract] [Full Text] [Related]

  • 59. Statistical considerations of FDA and CPMP rules for the investigation of new anti-bacterial products.
    Röhmel J.
    Stat Med; 2007 Sep 15; 20(17-18):2561-71. PubMed ID: 11523069
    [Abstract] [Full Text] [Related]

  • 60. ['Non-inferiority' trials. Tips for the critical reader. Research methodology 3].
    Soonawala D, Dekkers OM.
    Ned Tijdschr Geneeskd; 2012 Sep 15; 156(19):A4665. PubMed ID: 22571548
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.